Tumor Biology

, Volume 37, Issue 5, pp 5765–5768 | Cite as

RETRACTED ARTICLE: Downregulation of miR-148b as biomarker for early detection of hepatocellular carcinoma and may serve as a prognostic marker

  • Katayoun Ziari
  • Mojtaba Zarea
  • Masoumeh Gity
  • Amir Farshid Fayyaz
  • Emad Yahaghi
  • Ebrahim Khodaverdi Darian
  • Amir Masoud Hashemian
Original Article


MicroRNAs (miRNAs) have a large number of various target genes in different cancer types, which may result in many biological functions. Thus, identifying the molecular mechanisms of miRNAs may effect on the complexity of cancer progression via regulation of gene. In the current study, we utilized real-time PCR to quantify the diction of miR-148b in trail hepatocellular carcinoma (HCC) specimen and normal tissues. Furthermore, we evaluated the relationship of miR-148b and clinicopathological features with survival of HCC patients. Therefore, we evaluated the level of miR-148b expression in 101 HCC patients and also in 40 normal control cases. The result suggested lower expression in tumor tissues than normal control tissues (0.96 ± 0.14; 1.84 ± 0.20, P < 0.05). Our findings suggest that the declined expression of miR-148b can considerably be linked to tumor node metastasis (TNM) stage (stages III and IV; P = 0.021) and vein invasion (P = 0.029). Nevertheless, miR-148b expression was not related to sex (P = 0.674), age (P = 0. 523), size of tumor (P = 0.507), liver cirrhosis, and histologic grade (P = 0.734). Survival analysis showed that low expression was remarkably related to overall survival (P = 0.012). Furthermore, multivariate survival test suggested that decline of miR-148b diction was linked to poor survival in HCC patients. Our results suggested that miR-148b is decreased in HCC. Therefore, we concluded that miR-148b may play its role in the prognosis of HCC.


miRNA Liver Pathology Cancer PCR 



The authors thank Dr. Javad Javanbakht for his help with this manuscript.

Conflicts of interest



  1. 1.
    Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.CrossRefPubMedGoogle Scholar
  2. 2.
    Zheng B, Liang L, Wang C, Huang S, Cao X, Zha R, et al. MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. Clin Cancer Res. 2011;17:7574–83.CrossRefPubMedGoogle Scholar
  3. 3.
    Wu XJ, Li Y, Liu D, Zhao LD, Bai B, Xue MH. MiR-27a as an oncogenic microRNA of hepatitis B virus-related hepatocellular carcinoma. Asian Pac J Cancer Prev. 2013;14:885–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 2013;12:847–65.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010;11:597–610.PubMedGoogle Scholar
  6. 6.
    Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857–66.CrossRefPubMedGoogle Scholar
  7. 7.
    Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 2010;11:136–46.CrossRefPubMedGoogle Scholar
  8. 8.
    Zhao G, Zhang JG, Liu Y, Qin Q, Wang B, Tian K, et al. MiR-148b functions as a tumor suppressor in pancreatic cancer by targeting AMPKalpha1. Mol Cancer Ther. 2013;12:83–93.CrossRefPubMedGoogle Scholar
  9. 9.
    Azizi M, Teimoori-Toolabi L, Arzanani MK, Azadmanesh K, Fard-Esfahani P, Zeinali S. MicroRNA-148b and microRNA-152 reactivate tumor suppressor genes through suppression of DNA methyltransferase-1 gene in pancreatic cancer cell lines. Cancer Biol Ther. 2014;15(4):419–27.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Yang JD, Roberts LR. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin N Am. 2010;24(4):899–919.CrossRefGoogle Scholar
  11. 11.
    Zhang Z, Zheng W, Hai J. MicroRNA-148b expression is decreased in hepatocellular carcinoma and associated with prognosis. Med Oncol. 2014;31(6):984.CrossRefPubMedGoogle Scholar
  12. 12.
    Cimino D, De Pitta C, Orso F, Zampini M, Casara S, Penna E, et al. MiR148b is a major coordinator of breast cancer progression in a relapseassociated microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS, and CSF1. FASEB J. 2013;27:1223–35.CrossRefPubMedGoogle Scholar
  13. 13.
    Song YX, Yue ZY, Wang ZN, Xu YY, Luo Y, Xu HM. MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferation. Mol Cancer. 2011;10:1.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Liu GL, Liu X, Lv XB, Wang XP, Fang XS, Sang Y. miR-148b functions as a tumor suppressor in non-small cell lung cancer by targeting carcinoembryonic antigen (CEA). Int J Clin Exp Med. 2014;7:1990–9.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Song Y, Xu Y, Wang Z, Chen Y, Yue Z, Gao P. MicroRNA-148b suppresses cell growth by targeting cholecystokinin-2 receptor in colorectal cancer. Int J Cancer. 2012;131(5):1042–51.CrossRefPubMedGoogle Scholar
  16. 16.
    Cuk K, Zucknick M, Heil J, Madhavan D, Schott S, Turchinovich A, et al. Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer. 2013;132(7):1602–12.CrossRefPubMedGoogle Scholar
  17. 17.
    Chang H, Zhou X, Wang ZN, Song YX, Zhao F, Gao P, et al. Increased expression of miR-148b in ovarian carcinoma and its clinical significance. Mol Med Rep. 2012;5(5):1277–80.PubMedGoogle Scholar
  18. 18.
    Li L, Chen YY, Li SQ, Huang C, Qin YZ. Expression of miR-148/152 family as potential biomarkers in non-small-cell lung cancer. Med Sci Monit. 2015;21:1155–61.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Katayoun Ziari
    • 1
  • Mojtaba Zarea
    • 2
  • Masoumeh Gity
    • 3
  • Amir Farshid Fayyaz
    • 4
  • Emad Yahaghi
    • 5
  • Ebrahim Khodaverdi Darian
    • 6
  • Amir Masoud Hashemian
    • 7
  1. 1.Department of Pathology, Be’sat HospitalAJA University of Medical SciencesTehranIran
  2. 2.Center for Chemical BiologyIndian Institute of Chemical Technology (IICT)HyderabadIndia
  3. 3.Department of Radiology, Medical Imaging CenterTehran University of Medical SciencesTehranIran
  4. 4.Department of Legal MedicineAJA University of Medical SciencesTehranIran
  5. 5.Baqiyatallah University of Medical SciencesTehranIran
  6. 6.Young Researchers and Elite Club, Karaj BranchIslamic Azad UniversityKarajIran
  7. 7.Department of Emergency Medicine, Imam Reza Hospital, Faculty of MedicineMashhad University of Medical SciencesMashhadIran

Personalised recommendations